Download Investing in Biotechnology

Investing in
Biotechnology
Jessica Yu
Biotech 2
Company Description (Week 0 – 7)
Genentech, Inc. (DNA)
Genzyme Corp. (GENZ)
-
-
-
-
Goals: Discovering, developing,
manufacturing, and commercializing
biotherapeutics in the U.S.
Products: Avastin, Rituxan, Herceptin,
Lucentis, Xolair, Tarvceva, Nutropin,
Activase, TNKase, Cathflo Activase,
Pulmozyme, Raptiva,
Number of shares purchased: 7 shares
Price per share at purchase: $78.30
-
-
-
Located in the U.S. the European Union,
Latin America, and Asia Pacific
Consists of 5 specialized branches: Renal,
Therapeutics, Transplant, Biosurgery, and
Genetics
Products: Renagel, Hectoral vitamin D2 prehormone products, Cerezyme/Ceredase,
Fabrazyme, Thyrogen, Myozyme,
Aldurazyme, Thymoglobulin,
Lymphoglobuline, Synvisc, Sepra products,
Number of shares purchased:7 shares
Price per share at purchase: $64.07
Company Description (Week 8 - 15)
Questcor Pharmaceuticals,
Inc. (QSC)
-
-
Sangamo Biosciences
(SGMO)
Goals: Novel therapeutics for treating
diseases and diseases of the central nervous
system
Products: H.P. Acthar Gel, Doral
Number of shares purchased: 500 shares
Price per share at purchase: $1.37
-
Goals: Researching and developing novel
DNA-binding proteins for therapeutic
gene regulation and modification
Achievements: development of a class of
DNA-binding proteins, called zinc finger
DNA-binding proteints (ZFPs)
Number of shares purchased: 19 shares
Price per share at purchase: $18.86
Events Affecting Company Stocks
Genentech, Inc. (-)
- Alteration of a plan to discourage doctors from using Avastin to treat
eye disease because of FDA concerns, but it also may have damaged
Lucentis sales by angering retina specialists
Genzyme Corporation (+)
-
the U.S. Food and Drug Administration has granted Epicel, its product
for the treatment of life-threatening wounds resulting from severe
burns
Questcor Pharmaceuticals, Inc. (+)
- U.S. shipments of its main product Acthar, a hormone used to treat
swelling and allergic reactions, increased by 4 percent in December
from the previous month
Sangamo Biosciences (-)
-
Holder Kopp Investment Advisors cuts stake in Sangamo Biosciences
to 7.2 percent
Performance Graphs
Total Stock Values for 16 Weeks
Total Stock Value ($)
3000
DNA (7 shares)
QSC (500 shares)
GENZ (7 shares)
SGMO (19 shares)
2500
2000
1500
*DNA w as sw itched w ith QSC
after w eek 7
** GENZ w as sw itched w ith
SGMO after w eek 7
1000
500
0
0
2
4
6
8
Time (Weeks)
Price Per Share over 16 Weeks
DNA
GENZ
QSC
SMGO
Price per
per Share
($)($)
Price
Share
80
70
60
50
*DNA w as
sw itched w ith
QSC after w eek 7
** GENZ w as
sw itched w ith
SGMO after w eek
7
40
30
20
10
0
0
2
4
6
8
Time (Weeks)
10
12
14
16
10
12
14
Stock Investment Summary
- Total Stock Value at Purchase: $996.59
- Total Stock Value after 16 Weeks:
$3057.39
- Net profit: $2060.80
- Percent Increase from Original Stock
Value: +206.79%